MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs. 2009 Aug; 27(4):379-86.

View in: PubMed

subject areas

Aged
Cancer Vaccines
Disease Progression
Drug Administration Schedule
Humans
Immunotherapy
Injections, Subcutaneous
Interleukin-2
Male
Membrane Glycoproteins
Middle Aged
Mucin-1
Prostate-Specific Antigen
Prostatic Neoplasms
Time Factors
Treatment Outcome

authors with profiles

Walter M. Stadler